FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey N. Joyce

Research Profile

Chemicals & Drugs

Procedures

Autoradiography

Anatomy

Corpus Striatum

Living Beings

Disorders

Co-author Network

Publications

TOP 3
Jonathan Wills; Jessica Jones; Thomas Haggerty; Valeriy Duka; Jeffrey N. Joyce; Anita Sidhu
Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.
Stephen M Massa; Tao Yang; Youmei Xie; Jian Shi; Mehmet Bilgen; Jeffrey N. Joyce; Dean Nehama; Jayakumar Rajadas; Frank M Longo
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.
Alex V Iarkov; Terry C Der; Jeffrey N. Joyce
Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey N. Joyce (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Jonathan Wills; Jessica Jones; Thomas Haggerty; Valeriy Duka; Jeffrey N. Joyce; Anita Sidhu
Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.
Experimental neurology 2010;225(1):210-8.
2010: Stephen M Massa; Tao Yang; Youmei Xie; Jian Shi; Mehmet Bilgen; Jeffrey N. Joyce; Dean Nehama; Jayakumar Rajadas; Frank M Longo
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.
The Journal of clinical investigation 2010;120(5):1774-85.
2010: Alex V Iarkov; Terry C Der; Jeffrey N. Joyce
Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice.
European journal of pharmacology 2010;627(1-3):177-84.
2010: Alex V Yarkov; Terry C Der; Jeffrey N. Joyce
Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor.
European journal of pharmacology 2010;627(1-3):167-72.
2009: Diego Mastroeni; Andrew Grover; Brian Leonard; Jeffrey N. Joyce; Paul D Coleman; Brooke Kozik; Denise L Bellinger; Joseph Rogers
Microglial responses to dopamine in a cell culture model of Parkinson's disease.
Neurobiology of aging 2009;30(11):1805-17.
2009: Peter R Kufahl; Arturo R Zavala; Akanksha Singh; Kenneth J Thiel; Erin D Dickey; Jeffrey N. Joyce; Janet L Neisewander
c-Fos expression associated with reinstatement of cocaine-seeking behavior by response-contingent conditioned cues.
Synapse (New York, N.Y.) 2009;63(10):823-35.
2009: Tetyana Duka; Valeriy Duka; Jeffrey N. Joyce; Anita Sidhu
Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2009;23(9):2820-30.
2008: Arturo R Zavala; Tracy Osredkar; Jeffrey N. Joyce; Janet L Neisewander
Upregulation of Arc mRNA expression in the prefrontal cortex following cue-induced reinstatement of extinguished cocaine-seeking behavior.
Synapse (New York, N.Y.) 2008;62(6):421-31.
2008: E R Bychkov; Vsevolod V Gurevich; Jeffrey N. Joyce; Jeffrey L Benovic; Eugenia V Gurevich
Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.
Neurobiology of aging 2008;29(3):379-96.
2007: ANDREW LOCKHART; J R Lamb; Tracy Osredkar; Lucia I Sue; Jeffrey N. Joyce; L Ye; V Libri; D Leppert; Thomas Beach
PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.
Brain : a journal of neurology 2007;130(Pt 10):2607-15.
2007: Jeffrey N. Joyce; Mark J Millan
Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
Current opinion in pharmacology 2007;7(1):100-5.
2007: Joseph Rogers; Diego Mastroeni; Brian Leonard; Jeffrey N. Joyce; Andrew Grover
Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
International review of neurobiology 2007;82():235-46.
2005: Jeffrey N. Joyce; Mark J Millan
Dopamine D3 receptor antagonists as therapeutic agents.
Drug discovery today 2005;10(13):917-25.
2005: Shuichi Ueda; Shin-ichi Sakakibara; Kazuhiko Nakadate; Takahiro Noda; Motoo Shinoda; Jeffrey N. Joyce
Degeneration of dopaminergic neurons in the substantia nigra of zitter mutant rat and protection by chronic intake of Vitamin E.
Neuroscience letters 2005;380(3):252-6.
2004: Steven P Presgraves; Sabine Borwege; Mark J Millan; Jeffrey N. Joyce
Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Experimental neurology 2004;190(1):157-70.
2004: Janet L Neisewander; Rita A Fuchs; Ly T L Tran-Nguyen; Suzanne M Weber; Greg P Coffey; Jeffrey N. Joyce
Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(8):1479-87.
2004: Mark J Millan; Benjamin Di Cara; Michael Hill; Michael Jackson; Jeffrey N. Joyce; Jonathan M Brotchie; Steve McGuire; Alan R Crossman; Lance Smith; Peter Jenner; Alain Gobert; Jean-Louis Peglion; Mauricette Brocco
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):921-35.
2004: Jeffrey N. Joyce; T C Der; Lynn Renish; Tracy Osredkar; Diane Hagner; Maria Reploge; Shinichi Sakakibara; Shuichi Ueda
Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Experimental neurology 2004;187(1):178-89.
2004: Thomas Beach; Douglas G. Walker; Lucia I Sue; Amanda Newell; Charles H Adler; Jeffrey N. Joyce
Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers.
Journal of neuropathology and experimental neurology 2004;63(4):329-37.
2004: Jeffrey N. Joyce; Lynn Renish; Tracy Osredkar; Jon M Walro; Jan Kucera; Dean E Dluzen
Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations.
Synapse (New York, N.Y.) 2004;52(1):11-9.
2004: Jeffrey N. Joyce; Cheryl Woolsey; Han Ryoo; Sabine Borwege; Diane Hagner
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
BMC biology 2004;2():22.
2004: Dean E Dluzen; Janet L McDermott; Linda I Anderson; Jan Kucera; Jeffrey N. Joyce; Tracy Osredkar; Jon M Walro
Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice.
Neuroscience 2004;128(1):201-8.
2004: Steven P Presgraves; Tariq Ahmed; Sabine Borwege; Jeffrey N. Joyce
Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.
Neurotoxicity research 2004;5(8):579-98.
2003: Alex V Yarkov; Diane Hanger; Maria Reploge; Jeffrey N. Joyce
Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
Pharmacology, biochemistry, and behavior 2003;76(3-4):551-62.
2003: Jeffrey N. Joyce; Steven P Presgraves; Lynn Renish; Sabine Borwege; Tracy Osredkar; Diane Hagner; Maria Replogle; Mateo PazSoldan; Mark J Millan
Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
Experimental neurology 2003;184(1):393-407.
2002: Charles H Adler; Joseph Hentz; Jeffrey N. Joyce; Thomas Beach; John Caviness
Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors.
Parkinsonism & related disorders 2002;9(2):103-10.
2002: Jeffrey N. Joyce; Han Ryoo; Thomas Beach; John Caviness; Mark Stacy; EV Gurevich; Mark Reiser; Charles H Adler
Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.
Brain research 2002;955(1-2):138-52.
2001: EV Gurevich; Richard T Robertson; Jeffrey N. Joyce
Thalamo-cortical afferents control transient expression of the dopamine D(3) receptor in the rat somatosensory cortex.
Cerebral cortex (New York, N.Y. : 1991) 2001;11(8):691-701.
2001: Jeffrey N. Joyce
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.
Pharmacology & therapeutics 2001;90(2-3):231-59.
2001: Jeffrey N. Joyce
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Synapse (New York, N.Y.) 2001;40(2):137-44.
2000: EV Gurevich; Jeffrey Kordower; Jeffrey N. Joyce
Ontogeny of the dopamine D2 receptor mRNA expressing cells in the human hippocampal formation and temporal neocortex.
Journal of chemical neuroanatomy 2000;20(3-4):307-25.
2000: Jeffrey N. Joyce; K Yoshimoto; S Ueda
The zitter mutant rat exhibits loss of D3 receptors with degeneration of the dopamine system.
Neuroreport 2000;11(10):2173-5.
2000: EV Gurevich; Jeffrey N. Joyce
Dopamine D(3) receptor is selectively and transiently expressed in the developing whisker barrel cortex of the rat.
The Journal of comparative neurology 2000;420(1):35-51.
1999: Jeffrey N. Joyce; EV Gurevich
D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics.
Annals of the New York Academy of Sciences 1999;877():595-613.
1999: Shuang Y Ma; Brian Ciliax; Glenn T Stebbins; Syed Jaffar; Jeffrey N. Joyce; Elizabeth J Cochran; Jeffrey Kordower; Deborah C Mash; Allan Levey; Elliott J Mufson
Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra.
The Journal of comparative neurology 1999;409(1):25-37.
1999: EV Gurevich; J W Himes; Jeffrey N. Joyce
Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja.
The Journal of pharmacology and experimental therapeutics 1999;289(1):587-98.
1999: Bethany Neal-Beliveau; Jeffrey N. Joyce
Timing: A critical determinant of the functional consequences of neonatal 6-OHDA lesions.
Neurotoxicology and teratology 1999;21(2):129-40.
1999: EV Gurevich; Jeffrey N. Joyce
Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(1):60-80.
1998: Jeffrey N. Joyce; A M Murray; Howard I Hurtig; G L Gottlieb; John Q Trojanowski
Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(6):472-80.
1998: W S Thomas; Bethany Neal-Beliveau; Jeffrey N. Joyce
There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum.
Brain research. Developmental brain research 1998;111(1):99-106.
1998: Han Ryoo; D Pierrotti; Jeffrey N. Joyce
Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(5):788-97.
1998: Bethany Neal-Beliveau; Jeffrey N. Joyce
Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Developmental psychobiology 1998;32(4):313-26.
1998: Jeffrey N. Joyce; Amanda Myers; EV Gurevich
Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease.
Brain research 1998;784(1-2):7-17.
1997: EV Gurevich; Jeffrey Kordower; Jeffrey N. Joyce
Dopamine D2 receptor mRNA is expressed in maturing neurons of the human hippocampal and subicular fields.
Neuroreport 1997;8(16):3605-10.
1997: Jeffrey N. Joyce; G Smutzer; C J Whitty; Amanda Myers; Michael J Bannon
Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Movement disorders : official journal of the Movement Disorder Society 1997;12(6):885-97.
1997: EV Gurevich; Jeffrey N. Joyce
Alterations in the cortical serotonergic system in schizophrenia: a postmortem study.
Biological psychiatry 1997;42(7):529-45.
1997: S K Goldsmith; R M Shapiro; Jeffrey N. Joyce
Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study.
Archives of general psychiatry 1997;54(7):649-58.
1997: Jeffrey N. Joyce; James Meador-Woodruff
Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;16(6):375-84.
1997: Jeffrey N. Joyce; S G Goldsmith; EV Gurevich
Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
Journal of psychiatric research 1997;31(2):197-217.
1997: Lise Rioux; Paul Frohna; Jeffrey N. Joyce; Jay S Schneider
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Movement disorders : official journal of the Movement Disorder Society 1997;12(2):148-58.
1997: EV Gurevich; YM Bordelon; R M Shapiro; Steven E Arnold; Raquel E Gur; Jeffrey N. Joyce
Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
Archives of general psychiatry 1997;54(3):225-32.
1997: Paul Frohna; Bethany Neal-Beliveau; Jeffrey N. Joyce
Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions.
Synapse (New York, N.Y.) 1997;25(3):293-305.
1996: S K Goldsmith; Jeffrey N. Joyce
Dopamine D2 receptors are organized in bands in normal human temporal cortex.
Neuroscience 1996;74(2):435-51.
1996: M V Solbrig; George F Koob; Jeffrey N. Joyce; W Ian Lipkin
A neural substrate of hyperactivity in borna disease: changes in brain dopamine receptors.
Virology 1996;222(2):332-8.
1996: EV Gurevich; Jeffrey N. Joyce
Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(5):309-23.
1996: Jeffrey N. Joyce; Paul Frohna; Bethany Neal-Beliveau
Functional and molecular differentiation of the dopamine system induced by neonatal denervation.
Neuroscience and biobehavioral reviews 1996;20(3):453-86.
1995: Paul Frohna; Bethany Neal-Beliveau; Jeffrey N. Joyce
Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs.
Neuroscience 1995;68(2):505-18.
1995: A M Murray; F B Weihmueller; J F Marshall; Howard I Hurtig; G L Gottleib; Jeffrey N. Joyce
Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Annals of neurology 1995;37(3):300-12.
1995: S K Goldsmith; Jeffrey N. Joyce
Alterations in hippocampal mossy fiber pathway in schizophrenia and Alzheimer's disease.
Biological psychiatry 1995;37(2):122-6.
1995: Paul Frohna; D S Rothblat; Jeffrey N. Joyce; Jay S Schneider
Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Synapse (New York, N.Y.) 1995;19(1):46-55.
1994: N Lexow; Jeffrey N. Joyce; S J Kim; J Phillips; M F Casanova; E D Bird; J E Kleinman; Andrew Winokur
Alterations in TRH receptors in temporal lobe of schizophrenics: a quantitative autoradiographic study.
Synapse (New York, N.Y.) 1994;18(4):315-27.
1994: A M Murray; H L Ryoo; EV Gurevich; Jeffrey N. Joyce
Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(23):11271-5.
1994: J Ułas; F B Weihmuller; L C Brunner; Jeffrey N. Joyce; John F Marshall; Carl W Cotman
Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(11 Pt 1):6317-24.
1994: H L Ryoo; Jeffrey N. Joyce
Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer's disease.
The Journal of comparative neurology 1994;348(1):94-110.
1994: S K Goldsmith; Jeffrey N. Joyce
Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers.
Hippocampus 1994;4(3):354-73.
1993: Bethany Neal-Beliveau; Jeffrey N. Joyce
D1 and D2 dopamine receptors do not up-regulate in response to neonatal intrastriatal 6-hydroxydopamine lesions.
Neuroscience letters 1993;160(1):77-80.
1993: Paul Frohna; Bethany Neal-Beliveau; Jeffrey N. Joyce
Neonatal 6-OHDA lesions upregulate adult expression of tyrosine hydroxylase mRNA.
Neuroreport 1993;4(9):1095-8.
1993: Jeffrey N. Joyce; A Shane; N Lexow; Andrew Winokur; M F Casanova; J E Kleinman
Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;8(4):315-36.
1993: Jeffrey N. Joyce; C Kaeger; H Ryoo; S Goldsmith
Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease.
Neuroscience letters 1993;154(1-2):171-4.
1993: Bethany Neal-Beliveau; Jeffrey N. Joyce; Irwin Lucki
Serotonergic involvement in haloperidol-induced catalepsy.
The Journal of pharmacology and experimental therapeutics 1993;265(1):207-17.
1993: Jeffrey N. Joyce
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.
Brain research 1993;600(1):156-60.
1993: Jeffrey N. Joyce
The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.
Psychopharmacology 1993;112(1 Suppl):S16-34.
1993: Lise Rioux; Jeffrey N. Joyce
Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1993;6(3):199-210.
1992: A M Murray; H Ryoo; Jeffrey N. Joyce
Visualization of dopamine D3-like receptors in human brain with [125I]epidepride.
European journal of pharmacology 1992;227(4):443-5.
1992: B S Neal; Jeffrey N. Joyce
Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
Synapse (New York, N.Y.) 1992;11(1):35-46.
1992: Jeffrey N. Joyce; N Lexow; S J Kim; R Artymyshyn; S Senzon; D Lawrence; M F Cassanova; J E Kleinman; E D Bird; Andrew Winokur
Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics.
Synapse (New York, N.Y.) 1992;10(3):228-46.
1992: Jeffrey N. Joyce
Monoamine receptors, limbic pathology and schizophrenia.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():502A-503A.
1992: J E Kleinman; Marc Laruelle; Jeffrey N. Joyce; M F Casanova
Abnormalities of serotonergic neural transmission in prefrontal cortex in schizophrenia.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():397A-398A.
1991: Jeffrey N. Joyce
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.
Experimental neurology 1991;113(3):277-90.
1991: Jeffrey N. Joyce
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system.
Experimental neurology 1991;113(3):261-76.
1991: P A Rao; P B Molinoff; Jeffrey N. Joyce
Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study.
Brain research. Developmental brain research 1991;60(2):161-77.
1991: B S Neal; Jeffrey N. Joyce
Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Brain research. Developmental brain research 1991;60(2):105-13.
1991: Jeffrey N. Joyce; Aaron Janowsky; Kim A Neve
Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.
The Journal of pharmacology and experimental therapeutics 1991;257(3):1253-63.
1990: P R Lowenstein; Jeffrey N. Joyce; Joseph T Coyle; J F Marshall
Striosomal organization of cholinergic and dopaminergic uptake sites and cholinergic M1 receptors in the adult human striatum: a quantitative receptor autoradiographic study.
Brain research 1990;510(1):122-6.
1990: Jeffrey N. Joyce; Howard I Hurtig
Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplant.
Progress in brain research 1990;82():699-706.
1989: Jeffrey N. Joyce; Robert B Gibbs; Carl W Cotman; J F Marshall
Regulation of muscarinic receptors in hippocampus following cholinergic denervation and reinnervation by septal and striatal transplants.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1989;9(8):2776-91.
1989: John F Marshall; R Navarrete; Jeffrey N. Joyce
Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis.
Brain research 1989;493(2):247-57.
1989: Howard I Hurtig; Jeffrey N. Joyce; J R Sladek; John Q Trojanowski
Postmortem analysis of adrenal-medulla-to-caudate autograft in a patient with Parkinson's disease.
Annals of neurology 1989;25(6):607-14.
1988: John F Marshall; Jeffrey N. Joyce
Basal ganglia dopamine receptor autoradiography and age-related movement disorders.
Annals of the New York Academy of Sciences 1988;515():215-25.
1988: Jeffrey N. Joyce; Robert B Gibbs; Carl W Cotman; J F Marshall
Regulation of acetylcholine muscarinic receptors by embryonic septal grafts showing cholinergic innervation of host hippocampus.
Progress in brain research 1988;78():109-16.
1988: Jeffrey N. Joyce; N Lexow; E Bird; Andrew Winokur
Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
Synapse (New York, N.Y.) 1988;2(5):546-57.
1987: K J Rhodes; Jeffrey N. Joyce; D W Sapp; J F Marshall
[3H]hemicholinium-3 binding in rabbit striatum: correspondence with patchy acetylcholinesterase staining and a method for quantifying striatal compartments.
Brain research 1987;412(2):400-4.
1987: Jeffrey N. Joyce; J F Marshall
Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents.
Neuroscience 1987;20(3):773-95.
1986: Jeffrey N. Joyce; D W Sapp; J F Marshall
Human striatal dopamine receptors are organized in compartments.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(20):8002-6.
1986: Jeffrey N. Joyce; J F Marshall; Krystof Bankiewicz; I J Kopin; D M Jacobowitz
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Brain research 1986;382(2):360-4.
1986: Jeffrey N. Joyce; S K Loeschen; D W Sapp; J F Marshall
Age-related regional loss of caudate-putamen dopamine receptors revealed by quantitative autoradiography.
Brain research 1986;378(1):158-63.
1986: C Van Hartesveldt; Jeffrey N. Joyce
Effects of estrogen on the basal ganglia.
Neuroscience and biobehavioral reviews 1986;10(1):1-14.
1985: N Rowland; Jeffrey N. Joyce; L L Bellush
Stereotyped behavior and diabetes mellitus in rats: reduced behavioral effects of amphetamine and apomorphine and reduced in vivo brain binding of [3H]spiroperidol.
Behavioral neuroscience 1985;99(5):831-41.
1985: Jeffrey N. Joyce; S K Loeschen; J F Marshall
Dopamine D-2 receptors in rat caudate-putamen: the lateral to medial gradient does not correspond to dopaminergic innervation.
Brain research 1985;338(2):209-18.
1985: Jeffrey N. Joyce; J F Marshall
Striatal topography of D-2 receptors correlates with indexes of cholinergic neuron localization.
Neuroscience letters 1985;53(1):127-31.
1984: Jeffrey N. Joyce; C van Hartesveldt
Rotation and postural deviation elicited by microinjections of dopamine into medial and lateral regions of dorsal striatum.
Pharmacology, biochemistry, and behavior 1984;21(6):979-81.
1984: Jeffrey N. Joyce; E Montero; C Van Hartesveldt
Dopamine-mediated behaviors: characteristics of modulation by estrogen.
Pharmacology, biochemistry, and behavior 1984;21(5):791-800.
1984: Jeffrey N. Joyce; C Van Hartesveldt
Estradiol application to one striatum produces postural deviation to systemic apomorphine.
Pharmacology, biochemistry, and behavior 1984;20(4):575-81.
1984: Jeffrey N. Joyce; C Van Hartesveldt
Behaviors induced by intrastriatal dopamine vary independently across the estrous cycle.
Pharmacology, biochemistry, and behavior 1984;20(4):551-7.
1983: Jeffrey N. Joyce; R E Davis; C Van Hartesveldt
Systemic apomorphine reverses intrastriatal dopamine-induced contralateral deviation.
European journal of pharmacology 1983;87(2-3):283-9.
1983: Jeffrey N. Joyce
Multiple dopamine receptors and behavior.
Neuroscience and biobehavioral reviews 1983;7(2):227-56.
1982: Jeffrey N. Joyce; R L Smith; C van Hartesveldt
Estradiol suppresses then enhances intracaudate dopamine-induced contralateral deviation.
European journal of pharmacology 1982;81(1):117-22.
1981: Jeffrey N. Joyce; R E Davis; C Van Hartesveldt
Behavioral effects of unilateral dopamine injection into dorsal or ventral striatum.
European journal of pharmacology 1981;72(1):1-10.